Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1164) 1164
humans (1148) 1148
life sciences & biomedicine (1137) 1137
niacinamide - analogs & derivatives (897) 897
phenylurea compounds (894) 894
male (721) 721
benzenesulfonates - administration & dosage (603) 603
female (594) 594
animals (538) 538
biological and medical sciences (523) 523
benzenesulfonates - therapeutic use (517) 517
medical sciences (511) 511
oncology (496) 496
pyridines - administration & dosage (440) 440
sorafenib (423) 423
pyridines - therapeutic use (407) 407
middle aged (404) 404
aged (331) 331
benzenesulfonates - pharmacology (325) 325
antineoplastic agents - therapeutic use (300) 300
benzenesulfonates - adverse effects (299) 299
adult (285) 285
treatment outcome (285) 285
pyridines - adverse effects (262) 262
tumors (258) 258
kidney neoplasms - drug therapy (249) 249
pharmacology. drug treatments (238) 238
carcinoma, renal cell - drug therapy (237) 237
cancer (232) 232
mice (229) 229
antineoplastic agents (219) 219
pharmacology & pharmacy (208) 208
liver neoplasms - drug therapy (199) 199
care and treatment (196) 196
carcinoma, hepatocellular - drug therapy (193) 193
rats (191) 191
antineoplastic combined chemotherapy protocols - therapeutic use (190) 190
antineoplastic agents - administration & dosage (183) 183
antineoplastic agents - adverse effects (166) 166
pyridines - pharmacology (163) 163
protein kinase inhibitors - therapeutic use (162) 162
cell line, tumor (148) 148
research (144) 144
antimitotic agents (127) 127
kidney neoplasms - pathology (126) 126
dose-response relationship, drug (124) 124
aged, 80 and over (123) 123
bevacizumab (120) 120
drug therapy (116) 116
indoles - therapeutic use (116) 116
benzenesulfonates - pharmacokinetics (113) 113
medicine & public health (113) 113
pyrroles - therapeutic use (112) 112
protein kinase inhibitors - administration & dosage (111) 111
antibodies, monoclonal, humanized (106) 106
renal cell carcinoma (106) 106
hepatocellular carcinoma (104) 104
nephrology. urinary tract diseases (104) 104
kidneys (101) 101
time factors (100) 100
indoles - administration & dosage (99) 99
tumors of the urinary system (99) 99
neoplasms - drug therapy (98) 98
liver cancer (96) 96
administration, oral (95) 95
abridged index medicus (94) 94
benzenesulfonates (93) 93
antineoplastic agents - pharmacology (92) 92
drug administration schedule (91) 91
protein kinase inhibitors - adverse effects (91) 91
metastasis (89) 89
analysis (88) 88
chemotherapy (88) 88
disease models, animal (87) 87
gastroenterology & hepatology (86) 86
pyrroles - administration & dosage (86) 86
carcinoma, renal cell (85) 85
rats, sprague-dawley (85) 85
clinical trials as topic (84) 84
gastroenterology. liver. pancreas. abdomen (84) 84
prognosis (84) 84
disease-free survival (83) 83
vascular endothelial growth factor (82) 82
carcinoma, hepatocellular - pathology (81) 81
liver neoplasms - pathology (81) 81
sunitinib (81) 81
antineoplastic combined chemotherapy protocols - adverse effects (80) 80
angiogenesis inhibitors - therapeutic use (77) 77
health aspects (76) 76
liver. biliary tract. portal circulation. exocrine pancreas (76) 76
retrospective studies (76) 76
mice, nude (75) 75
neoplasm staging (75) 75
carcinoma, renal cell - secondary (74) 74
cell proliferation - drug effects (72) 72
hepatoma (72) 72
urology & nephrology (72) 72
carcinoma, renal cell - pathology (71) 71
sirolimus - analogs & derivatives (71) 71
survival rate (70) 70
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1425) 1425
German (25) 25
Russian (18) 18
Japanese (15) 15
French (13) 13
Chinese (8) 8
Spanish (7) 7
Italian (4) 4
Hungarian (3) 3
Polish (2) 2
Czech (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
by Bo Gao and Shang Yeap and Arthur Clements and Bavanthi Balakrishnar and Mark Wong and Howard Gurney
Journal of clinical oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines – Lessons for design of combination targeted therapy
by Park, Brian J and Whichard, Zakary L and Corey, Seth J
Cancer letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
by Toni K. Choueiri and Fabio A.B. Schutz and Youjin Je and Jonathan E. Rosenberg and Joaquim Bellmunt
Journal of clinical oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 13, pp. 2280 - 2285
Life Sciences & Biomedicine | Oncology | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Medical sciences | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Blood and lymphatic vessels | Tumors | Niacinamide - analogs & derivatives | Thromboembolism - chemically induced | Humans | Middle Aged | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thromboembolism - epidemiology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Incidence | Angiogenesis Inhibitors - administration & dosage | Pyridines - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Angiogenesis Inhibitors - adverse effects | Arterial Occlusive Diseases - chemically induced | Pyridines - administration & dosage | Risk Assessment | Administration, Oral | Risk Factors | Arterial Occlusive Diseases - epidemiology | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
by Hutson, Thomas E and Figlin, Robert A and Kuhn, John G and Motzer, Robert J
The oncologist (Dayton, Ohio), ISSN 1083-7159, 10/2008, Volume 13, Issue 10, pp. 1084 - 1096
Dosing | Temsirolimus | Sunitinib | Safety | Renal cell carcinoma | Sorafenib | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Recombinant Proteins | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Carcinoma, Renal Cell - drug therapy | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Carcinoma, Renal Cell - pathology | Interferon-alpha - administration & dosage | Sirolimus - administration & dosage | Indoles - adverse effects | Antibodies, Monoclonal - administration & dosage | Kidney Neoplasms - pathology | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Multifunctional Molecular Therapeutic Agent for Targeted and Controlled Dual Chemo- and Photodynamic Therapy
by Ha, Summer Y. Y and Zhou, Yimin and Fong, Wing-Ping and Ng, Dennis K. P
Journal of medicinal chemistry, ISSN 0022-2623, 08/2020, Volume 63, Issue 15, pp. 8512 - 8523
Prodrugs - administration & dosage | Glutathione - metabolism | Bibenzyls - pharmacokinetics | Humans | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Photochemotherapy | Indoles - administration & dosage | Drug Delivery Systems | Photosensitizing Agents - administration & dosage | Benzenesulfonates - pharmacokinetics | Benzenesulfonates - pharmacology | Photosensitizing Agents - pharmacology | Indoles - pharmacology | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Bibenzyls - administration & dosage | HCT116 Cells | Organometallic Compounds - pharmacokinetics | Hep G2 Cells | Neoplasms - drug therapy | Prodrugs - pharmacokinetics | Photosensitizing Agents - pharmacokinetics | Indoles - pharmacokinetics | Bibenzyls - pharmacology | Prodrugs - pharmacology | Organometallic Compounds - pharmacology | Organometallic Compounds - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat
by Wang, Xue-qing and Fan, Jie-ming and Liu, Ya-ou and Zhao, Bo and Jia, Zeng-rong and Zhang, Qiang
International journal of pharmaceutics, ISSN 0378-5173, 2011, Volume 419, Issue 1, pp. 339 - 346
Suspension | Oral bioavailability | pH-sensitive nanoparticles | Nanomatrix | Sorafenib | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pharmaceutical technology. Pharmaceutical industry | Biological and medical sciences | Medical sciences | General pharmacology | Pharmacology. Drug treatments | Niacinamide - analogs & derivatives | Pyridines - administration & dosage | Administration, Oral | Area Under Curve | Adhesiveness | Silicon Dioxide - chemistry | Solubility | Pyridines - pharmacokinetics | Rats | Biological Availability | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Nanostructures | Polymethacrylic Acids - chemistry | Rats, Sprague-Dawley | Nanoparticles | Benzenesulfonates - pharmacokinetics | Animals | Antineoplastic Agents - pharmacokinetics | Porosity | Suspensions | Hydrogen-Ion Concentration | Antimitotic agents | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
by Nilofer S. Azad and Edwin M. Posadas and Virginia E. Kwitkowski and Seth M. Steinberg and Lokesh Jain and Christina M. Annunziata and Lori Minasian and Gisele Sarosy and Herbert L. Kotz and Ahalya Premkumar and Liang Cao and Deborah McNally and Catherine Chow and Helen X. Chen and John J. Wright and William D. Figg and Elise C. Kohn
Journal of clinical oncology, ISSN 0732-183X, 08/2008, Volume 26, Issue 22, pp. 3709 - 3714
Biological and medical sciences | Medical sciences | Tumors | Niacinamide - analogs & derivatives | raf Kinases - antagonists & inhibitors | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Ovarian Neoplasms - drug therapy | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Vascular Endothelial Growth Factor A - blood | Neoplasms - enzymology | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Neoplasms - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
by Ghassan K. Abou-Alfa and Lawrence Schwartz and Sergio Ricci and Dino Amadori and Armando Santoro and Arie Figer and Jacques De Greve and Jean-Yves Douillard and Chetan Lathia and Brian Schwartz and Ian Taylor and Marius Moscovici and Leonard B. Saltz
Journal of clinical oncology, ISSN 0732-183X, 09/2006, Volume 24, Issue 26, pp. 4293 - 4300
Gastroenterology. Liver. Pancreas. Abdomen | Biological and medical sciences | Medical sciences | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Tumors | Niacinamide - analogs & derivatives | Predictive Value of Tests | Extracellular Signal-Regulated MAP Kinases - blood | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | RNA, Neoplasm - blood | Benzenesulfonates - adverse effects | Liver Neoplasms - blood | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Carcinoma, Hepatocellular - genetics | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Carcinoma, Hepatocellular - blood | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Treatment Outcome | Biomarkers, Tumor - blood | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study
by Lamberts, Laetitia E and Koch, Maximillian and de Jong, Johannes S and Adams, Arthur and Glatz, Juergen and Kranendonk, Marriette E G and Terwisscha van Scheltinga, Anton G T and Jansen, Liesbeth and de Vries, Jakob and Lub-de Hooge, Marjolijn N and Schröder, Carolien P and Jorritsma-Smit, Annelies and Linssen, Matthijs D and Boer, de, Esther and van der Vegt, Bert and Nagengast, Wouter B and Elias, Sjoerd G and Oliveira, Sabrina and Witkamp, Arjen and Mali, Willem P Th M and van der Wall, Elsken and Van Diest, Paul J and de Vries, Elisabeth G and Ntziachristos, Vasilis and van Dam, Gooitzen M
Clinical cancer research, ISSN 1078-0432, 06/2017, Volume 23, Issue 11, pp. 2730 - 2741
ANTIBODIES | INDOCYANINE GREEN | IN-111-BEVACIZUMAB | ANGIOGENESIS | SAFETY | CONSERVING SURGERY | MARGINS | OVARIAN-CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Life Sciences & Biomedicine | Oncology | Science & Technology | Optical Imaging | Bevacizumab - adverse effects | Humans | Male | Positron-Emission Tomography | Benzenesulfonates - administration & dosage | Vascular Endothelial Growth Factor A - genetics | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Feasibility Studies | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms, Male - diagnostic imaging | Female | Breast Neoplasms - diagnostic imaging | Antibodies, Monoclonal, Humanized - adverse effects | Breast Neoplasms, Male - diagnosis | Tissue Distribution - drug effects | Bevacizumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Breast Neoplasms - drug therapy | Indoles - adverse effects | Breast Neoplasms - pathology | Cell Line, Tumor | Breast Neoplasms - diagnosis | Breast Neoplasms, Male - pathology | Multiplexing | Drug delivery systems | Intravenous administration | Invasiveness | Feasibility studies | Fluorescence | I.R. radiation | Breast cancer | Patients | Bevacizumab | Surgical instruments | Histopathology | Microscopy | Experimental design | Surgery | In vivo methods and tests | Safety | Vascular endothelial growth factor | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Advanced-stage hepatocellular carcinoma: Transarterial chemoembolization versus sorafenib
by Pinter, Matthias and Hucke, Florian and Graziadei, Ivo and Vogel, Wolfgang and Maieron, Andreas and Königsberg, Robert and Stauber, Rudolf and Grünberger, Birgit and Müller, Christian and Kölblinger, Claus and Peck-Radosavljevic, Markus and Sieghart, Wolfgang
Radiology, ISSN 0033-8419, 2012, Volume 263, Issue 2, pp. 590 - 599
Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Liver Neoplasms - therapy | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Ethiodized Oil - adverse effects | Benzenesulfonates - adverse effects | Chemoembolization, Therapeutic - methods | Ethiodized Oil - administration & dosage | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Contrast Media - administration & dosage | Adult | Female | Liver Neoplasms - pathology | Retrospective Studies | Doxorubicin - administration & dosage | Pyridines - administration & dosage | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Chi-Square Distribution | Disease Progression | Magnetic Resonance Imaging | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Carcinoma, Hepatocellular - therapy | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
by Lee, W.J and Lee, J.L and Chang, S.E and Lee, M.W and Kang, Y.K and Choi, J.H and Moon, K.C and Koh, J.K
British journal of dermatology (1951), ISSN 0007-0963, 11/2009, Volume 161, Issue 5, pp. 1045 - 1051
sunitinib | sorafenib | cutaneous adverse effects | Cutaneous adverse effects | Sunitinib | Sorafenib | Life Sciences & Biomedicine | Dermatology | Science & Technology | Biological and medical sciences | Medical sciences | Niacinamide - analogs & derivatives | Humans | Middle Aged | Hand Dermatoses - chemically induced | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Skin Diseases - pathology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Retrospective Studies | Carcinoma, Renal Cell - drug therapy | Drug Eruptions - etiology | Skin Diseases - chemically induced | Pyridines - administration & dosage | Administration, Oral | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Stomatitis - chemically induced | Foot Dermatoses - chemically induced | Alopecia - chemically induced | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Liver cancer | Medical colleges | Care and treatment | Antineoplastic agents | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights